Bio-Techne Corp
$ 49.77
-2.01%
02 Jun - close price
- Market Cap 7,952,127,000 USD
- Current Price $ 49.77
- High / Low $ 50.41 / 49.27
- Stock P/E 72.56
- Book Value 12.90
- EPS 0.70
- Next Earning Report 2026-08-05
- Dividend Per Share $0.32
- Dividend Yield 0.62 %
- Next Dividend Date -
- ROA 0.07 %
- ROE 0.05 %
- 52 Week High 71.93
- 52 Week Low 43.12
About
Bio-Techne Corporation develops, manufactures, and sells life science reagents, instruments, and services for the global clinical diagnostic and research markets. The company is headquartered in Minneapolis, Minnesota.
Analyst Target Price
$61.42
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-06 | 2026-02-04 | 2025-11-05 | 2025-08-06 | 2025-05-07 | 2025-02-05 | 2024-10-30 | 2024-08-07 | 2024-05-01 | 2024-02-01 | 2023-10-31 | 2023-08-08 |
| Reported EPS | 0.53 | 0.46 | 0.24 | 0.53 | 0.56 | 0.42 | 0.42 | 0.49 | 0.48 | 0.4 | 0.41 | 0.55 |
| Estimated EPS | 0.53 | 0.43 | 0.25 | 0.5 | 0.51 | 0.39 | 0.38 | 0.49 | 0.46 | 0.41 | 0.44 | 0.55 |
| Surprise | 0 | 0.03 | -0.01 | 0.03 | 0.05 | 0.03 | 0.04 | 0 | 0.02 | -0.01 | -0.03 | 0 |
| Surprise Percentage | 0% | 6.9767% | -4% | 6% | 9.8039% | 7.6923% | 10.5263% | 0% | 4.3478% | -2.439% | -6.8182% | 0% |
Next Quarterly Earnings
| Jun 2026 | |
|---|---|
| Reported Date | 2026-08-05 |
| Fiscal Date Ending | 2026-06-30 |
| Estimated EPS | 0.52 |
| Currency | USD |
Previous Dividend Records
| May 2026 | Feb 2026 | Nov 2025 | Aug 2025 | May 2025 | Feb 2025 | Jan 1970 | Nov 2024 | Aug 2024 | May 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Payment Date | 2026-05-29 | 2026-02-27 | 2025-11-28 | 2025-08-29 | 2025-05-30 | 2025-02-28 | None | 2024-11-22 | 2024-08-30 | 2024-05-24 |
| Amount | $0.08 | $0.08 | $0.08 | $0.08 | $0.08 | $0.08 | $0.08 | $0.08 | $0.08 | $0.08 |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: TECH
2026-06-02 08:34:00
Bio-techne Corp (TECH) shows strong near and mid-term sentiment, potentially extending long-term, with an exceptional 57.1:1 risk-reward setup targeting a 16.5% gain. AI models suggest specific position, momentum, and risk hedging strategies, highlighting positive sentiment and key support/resistance levels across different time horizons.
2026-06-01 17:17:00
Bio-Techne Corp. shares (TECH) fell 1.72% to $50.79 on Monday, despite a general uptrend in the stock market with both the S&P 500 and Dow Jones Industrial Average posting gains. This decline broke a three-day winning streak for the company's stock.
2026-06-01 09:08:40
Bio-Techne Corporation (NASDAQ: TECH) is a biotechnology company with a market capitalization of $8.09 billion, offering life science reagents, instruments, and services. Analysts currently project an average target price of $61.42, suggesting a potential upside of 18.84% from its current price of $51.68. Despite a decline in revenue growth, the company demonstrates financial strength with a robust free cash flow and positive analyst sentiment, though technical indicators suggest bearish momentum.
2026-05-29 17:17:00
Shares of Bio-Techne Corp. (TECH) increased by 1.65% to $51.68 on Friday, outperforming its competitors. This rise occurred during a generally favorable trading session, with the S&P 500 Index and the Dow Jones Industrial Average also seeing gains. This marks the third consecutive day of gains for Bio-Techne Corp. stock.
2026-05-29 15:08:21
Citi has reiterated its Buy rating on Bio-Techne (TECH.US) and maintained its target price at $70. This indicates a continued positive outlook from the financial institution regarding the company's stock performance.
2026-05-29 14:40:18
Analysts have provided their insights on several healthcare companies. Quanterix (QTRX) received a Hold rating from Canaccord Genuity and an upgrade to Hold from TipRanks – Anthropic. Bio-Techne (TECH) maintains a Buy rating from Citi, and Agilent (A) received a Buy rating from Stifel Nicolaus, with RBC Capital also initiating coverage with a Buy rating for both Bio-Techne and Agilent.
